ArticleBMC urology2025
Clinical features analysis of inflammatory myofibroblastic tumors of the retroperitoneal and genitourinary system.
Article in BMC urology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
objectiveTo explore the clinical features of inflammatory myofibroblastic tumors (IMT) of the retroperitoneal and genitourinary system.
methodsWe conducted a retrospective analysis of the clinical data of 23 patients with pathologically confirmed retroperitoneal and urogenital inflammatory myofibroblastic tumours who were admitted to the First Affiliated Hospital of Xiamen University between January 2010 and December 2024.
resultsThere were 10 male patients and 13 female patients, with an average age of (42.1 ± 4.1) years. The tumors were located in the retroperitoneum in 8 cases, in the bladder in 5 cases, in the kidney in 5 cases, in the spermatic cord in 2 cases, in the testis in 1 case, in the epididymis in 1 case, and in the prostate in 1 case. All 23 patients were diagnosed with space-occupying lesions before surgery.Among the 23 cases, 19 underwent surgical treatment and 4 received conservative treatment.Seven patients received postoperative adjuvant treatment. Among them, 4 patients received non-steroidal anti-inflammatory drug treatment, 3 patients had no recurrence and are currently alive, and 1 patient had recurrence and died; 1 patient received treatment with epirubicin and cisplatin, had no recurrence and is currently alive; 1 patient was treated with ifosfamide combined with epirubicin and pirarubicin, had no recurrence and is currently alive; 1 patient was treated with azathioprine and crizotinib, had no recurrence and is currently alive. As of the last follow-up, 2 patients had died, and the rest were all alive.
conclusionIMT can originate from any part of the genitourinary system, with pain being the most common symptom. Its clinical management is similar to that of malignant tumours of the genitourinary system, and complete surgical resection is the standard treatment strategy for all genitourinary IMT.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.